Zydus Receives Final Approval From The USFDA For Balsalazide Disodium Capsules

Zydus Receives Final Approval From The USFDA For Balsalazide Disodium Capsules

The product will be manufactured at the group’s formulation manufacturing facility in SEZ, Ahmedabad.

FPJ Web DeskUpdated: Saturday, June 10, 2023, 02:50 PM IST
article-image
Zydus Receives Final Approval From The USFDA For Balsalazide Disodium Capsules | Image: Zydus (Representative)

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) for Balsalazide Disodium Capsules USP, 750 mg, the company announced through an exchange filing.

The product will be manufactured at the group’s formulation manufacturing facility in SEZ, Ahmedabad.

Balsalazide Disodium Capsules USP, 750 mg had annual sales of USD 29 mn in the United States (IQVIA MAT April 2023).

Balsalazide Disodium is used to treat bowel diseases like ulcerative colitis. It helps reduce symptoms of ulcerative colitis such as diarrhea, rectal bleeding, and stomach pain. Balsalazide belongs to a class of drugs known as aminosalicylates and works by reducing swelling in the colon. (India).

The group now has 372 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.

(To receive our E-paper on WhatsApp daily, please click here.  To receive it on Telegram, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

RECENT STORIES

Uttarakhand CM Dhami Signs MoUs Worth ₹3,000 Crore On Day 3 Of Global Investors' Summit In London

Uttarakhand CM Dhami Signs MoUs Worth ₹3,000 Crore On Day 3 Of Global Investors' Summit In London

Saregama Acquires Majority Stake In Digital Entertainment Company Pocket Aces

Saregama Acquires Majority Stake In Digital Entertainment Company Pocket Aces

Godrej Agrovet Announces Stock Options To Eligible Employees

Godrej Agrovet Announces Stock Options To Eligible Employees

28% GST On Online Gaming, Casinos & Horse Racing From October 1: CBIC Chief

28% GST On Online Gaming, Casinos & Horse Racing From October 1: CBIC Chief

Emami Enters Into Definitive Agreement To Acquire 26% Of Shareholding Of Axiom Ayurveda

Emami Enters Into Definitive Agreement To Acquire 26% Of Shareholding Of Axiom Ayurveda